Lowering inflammation to address residual CV risk
Dr. Paul M. Ridker explains the concept of residual inflammatory risk. Currently, trials are investigating whether lowering inflammatory components might reduce CV event rates.
This video was recorded during ACC 2017, Washington DC, USA. PACE-cme did not receive financial support for the production of this video.
The educational content reflects the personal opinion of the expert.
Dr. Paul M. Ridker is director of the Center for Cardiovascular Disease Prevention, a translational research unit at Brigham and Women’s Hospital. A cardiovascular medicine specialist, he is also the Eugene Braunwald Professor of Medicine at Harvard School of Medicine.